Wuxi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company primarily in the People’s Republic of China and the United States. It operates in two segments, Laboratory Services and Manufacturing Services. The Laboratory Services segment offers synthetic chemistry, discovery biology, medicinal and analytical chemistry, DMPK/ADME, formulation process chemistry, cell line and bioprocess development, toxicology, safety pharmacology, clinical development, bioanalytical services, genomics, and research reagent production services for pharmaceutical, biotechnology, and medical device companies, as well as testing services for biologics, medical devices, and combination products. The Manufacturing Services segment engages in the production of manufacturing advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products; and advanced intermediates that are used as ingredients in small-molecule commercial products. The company sells its products directly to pharmaceutical, biotechnology, and medical device companies. Wuxi PharmaTech (Cayman) Inc. was founded in 2000 and is headquartered in Shanghai, the People’s Republic of China.